心肌梗塞中的高极化激活循环核酸通道抑制剂:除了心率调节之外的潜在益处
Adivitch Sripusanapan1,2,3, Panat Yanpiset1,2,3, Sirawit Sriwichaiin1,2,3
1Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Acta physiologica (Oxford, England)
|January 17, 2024
概括
伊瓦布拉丁在心肌梗塞 (MI) 后提供心脏保护,而不仅仅是减缓心率. 本综述探讨了其机制,包括线粒体保护和改善自,用于治疗心力衰竭幸存者.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 心肌梗塞 (MI) 导致心肌细胞损失,心脏重塑和慢性心力衰竭,对全球死亡率作出重大贡献.
- 伊瓦布拉丁是一种心率降低药物,向心脏起器细胞中的高极化激活循环核酸门 (HCN) 通道.
- 在心脏病发作后的非心脏起器心肌细胞中,HCN通道的宫外表达表明了伊瓦布拉丁的潜在替代作用.
研究的目的:
- 在心肌梗塞的背景下审查和讨论 ivabradine 的心脏保护机制,这些机制独立于心率降低.
- 探索艾瓦布拉丁在心脏病后心脏中发挥有益作用的分子途径.
主要方法:
- 对研究艾瓦布拉丁在心肌梗塞模型中的作用的文献综述.
- 分析着重于超越心率调节的分子机制的研究.
- 综合关于伊瓦布拉丁对细胞过程的影响的证据,如线粒体功能,自,循环,电生理学和矩阵金属蛋白酶.
主要成果:
- 越来越多的证据表明,伊瓦布拉丁具有独立于其降心率作用的心脏保护性质.
- 这些效应包括预防活性氧物种诱导的线粒体损伤,增强自系统,调节细胞内循环.
- 伊瓦布拉丁还修改了心室电生理学,并调节了矩阵金属蛋白酶,有助于其在MI后的保护作用.
结论:
- 伊瓦布拉丁通过多种分子机制在心肌梗塞中显示出显著的心脏保护潜力.
- 这些非心率降低效应为治疗心脏衰竭提供了新的治疗策略,以治疗心脏病发作后的心脏病发作.
- 对这些机制的进一步研究可以优化伊瓦布拉丁在心血管疾病中的临床应用.
更多相关视频
相关概念视频
G-Protein Gated Ion Channels
4.6K
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
Sensory...
4.6K
Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
518
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
518
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
836
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
836
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K


